lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-02 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
=== Audiobook === An audiobook version of Ubik was released in 2008 by Blackstone Audio. The audiobook, read by Anthony Heald, is unabridged and runs approximately 7 hours over 6 CDs. Another version released in 2016 by Brilliance Audio, read by Luke Daniels, is unabridged and runs 7 hrs 56 minutes.
30 October – A study finds that the world's remaining carbon budget for 1.5 °C of global warming is only half that of previous estimates, at less than 250 gigatonnes of carbon dioxide, or around six years of annual worldwide emissions. 31 October The first discovery of a virus, phage MiniFlayer, that attaches to another helper virus is reported. The coalition of research organizations and science funders behind Plan S publishes a proposal for moving scholarly communication towards open science practices that are more transparent, accessible, efficient and without author fees. Hazard research is published: a study further confirms noncompensable moist heat extremes will be beyond bounds of past human evolutionary environments for billions of people (9 Oct), an analysis calls for health policy regarding unhealthy ultra-processed foods (9 Oct), an analysis calls for action regarding the summarized environmental footprint of bitcoin mining (9 Oct), a global assessment of risk from increasing pollinator loss to crop pollination shows cocoa and coffee at high risk (12 Oct), a training data poisoning technique, 'Nightshade', against generative AI software specific to select prompts is described (20 Oct), a study indicates low deep sleep percentage is a modifiable dementia risk factor (30 Oct).
Ghana produces and exports hydrocarbons such as sweet crude oil and natural gas. The 100%-state-owned filling station company, Ghana Oil Company, is the number one petroleum and gas filling station, and the 100%-state-owned state oil company Ghana National Petroleum Corporation oversees hydrocarbon exploration and production of petroleum and natural gas reserves. Ghana aims to further increase the output of oil to 2.2 million barrels (350,000 m3) per day and gas to 34,000,000 cubic metres (1.2×10^9 cu ft) per day. The Jubilee Oil Field, which contains up to 3 billion barrels (480,000,000 m3) of sweet crude oil, was discovered in 2007. Ghana is believed to have up to 5 billion barrels (790,000,000 m3) to 7 billion barrels (1.1×109 m3) of petroleum in reserves, which is the fifth-largest in Africa and the 21st-to-25th-largest proven reserves in the world. It also has up to 1.7×1011 cubic metres (6×10^12 cu ft) of natural gas in reserves. The government has drawn up plans to nationalise petroleum and natural gas reserves to increase government revenue. In 2015, Ghana produced 88 metric tonnes of gold as per the Our World in Data report. As of 2019, Ghana was the 7th largest producer of gold in the world, producing ~140 tonnes that year. This record saw Ghana surpass South Africa in output for the first time, making Ghana the largest gold producer in Africa. In addition to gold, Ghana exports silver, timber, diamonds, bauxite, and manganese, and has other mineral deposits. Ghana ranks 9th in the world in diamond export and reserve size.
Sources: en.wikipedia.org
In October 2006, the X Prize Foundation established an initiative to promote the development of full genome sequencing technologies, called the Archon X Prize, intending to award $10 million to "the first Team that can build a device and use it to sequence 100 human genomes within 10 days or less, with an accuracy of no more than one error in every 100,000 bases sequenced, with sequences accurately covering at least 98% of the genome, and at a recurring cost of no more than $10,000 (US) per genome." Each year the National Human Genome Research Institute, or NHGRI, promotes grants for new research and developments in genomics. 2010 grants and 2011 candidates include continuing work in microfluidic, polony and base-heavy sequencing methodologies.
==== Mass spectrometry ==== Use of mass spectrometry as a second component of an operando experiment allows for optical spectra to be obtained before obtaining a mass spectrum of the analytes. Electrospray ionization allows a wider range of substances to be analysed than other ionization methods, due to its ability to ionize samples without thermal degradation. In 2017, Prof. Frank Crespilho and coworks introduced a new approach to operando DEMS, aiming the enzyme activity evaluation by differential electrochemical mass spectrometry (DEMS). NAD-dependent alcohol dehydrogenase (ADH) enzymes for ethanol oxidation were investigated by DEMS. The broad mass spectra obtained under bioelectrochemical control and with unprecedented accuracy were used to provide new insight into the enzyme kinetics and mechanisms.
== M == Magnetic resonance imaging (MRI) A non-invasive imaging technique that uses magnetic fields and radio waves to visualize detailed structures of the brain and other tissues. Malleus One of the three auditory ossicles in the middle ear. It transmits sound vibrations from the eardrum to the incus. Mammillary bodies Small round structures located in the hypothalamus involved in memory processing. Often damaged in Korsakoff syndrome. MAPK/ERK pathway A cellular signaling cascade involved in growth, differentiation, and survival. It plays roles in synaptic plasticity and neurodegeneration. Medial geniculate nucleus A relay center in the thalamus for auditory information, sending signals from the inner ear to the auditory cortex. Medial longitudinal fasciculus A bundle of nerve fibers in the brainstem involved in coordinating eye movements and head motion, especially during the vestibulo-ocular reflex. Medulla oblongata The lower part of the brainstem, responsible for autonomic functions such as respiration, heart rate, and blood pressure. Melatonin A hormone produced by the pineal gland that regulates circadian rhythms and the sleep–wake cycle. Secretion is influenced by light exposure. Memory The mental capacity to encode, store, and retrieve information. Subtypes include working memory, short-term memory, and long-term memory. Meninges The three protective membranes—dura mater, arachnoid mater, and pia mater—that surround the brain and spinal cord. Merkel cell A mechanoreceptor found in the skin involved in the sense of touch, particularly pressure and texture.
=== Radiation characteristics === Flurpiridaz (18F) has a halflife of 109.8 minutes and the main photons useful for imaging are those resulting from gamma decay through interaction of the positron with an electron.
Sources: en.wikipedia.org
With time, the mechanical complexity of TSP was simplified, and this interface became popular as the first ideal LC–MS interface for pharmaceutical applications comprising the analysis of drugs, metabolites, conjugates, nucleosides, peptides, natural products, and pesticides. The introduction of TSP marked a significant improvement for LC–MS systems and was the most widely applied interface until the beginning of the 1990s, when it began to be replaced by interfaces involving atmospheric pressure ionization (API).
Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, chronic neuropathic pain, fibromyalgia, and menopausal symptoms. Off-label uses include treatments for attention deficit hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters. Since norepinephrine pathways play a role in pain modulation, SNRIs are also widely used for chronic pain conditions such as neuropathic pain and fibromyalgia. The human serotonin transporter (SERT) and norepinephrine transporter (NET) are membrane transport proteins that are responsible for the reuptake of serotonin and norepinephrine from the synaptic cleft back into the presynaptic nerve terminal. Dual inhibition of serotonin and norepinephrine reuptake can offer advantages over other antidepressant drugs by treating a wider range of symptoms. They can be especially useful in concomitant chronic or neuropathic pain. SNRIs, along with SSRIs and NRIs, are second-generation antidepressants.
Because of the practical and, in particular, the financial scale of the program needed, the NCI decided to seek association with a pharmaceutical company, and in August 1989, it published a Cooperative Research and Development Agreement (CRADA) offering its current stock and supply from current bark stocks, and proprietary access to the data so far collected, to a company willing to commit to providing the funds to collect further raw material, isolate taxol, and fund a large proportion of clinical trials. In the words of Goodman and Welsh, authors of a substantial scholarly book on taxol, "The NCI was thinking, not of collaboration, ... but of a hand-over of taxol (and its problems)". Although the offer was widely advertised, only four companies responded to the CRADA, including the American firm Bristol-Myers Squibb (BMS), which was selected as the partner in December 1989. The choice of BMS later became controversial and was the subject of Congressional hearings in 1991 and 1992. While it seems clear the NCI had little choice but to seek a commercial partner, there was also controversy about the terms of the deal, eventually leading to a report by the General Accounting Office in 2003, which concluded the NIH had failed to ensure value for money. In related CRADAs with the USDA and Department of the Interior, Bristol-Myers Squibb was given exclusive first refusal on all Federal supplies of Taxus brevifolia. This exclusive contract lead to some criticism for giving BMS a "cancer monopoly".
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.